Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot

Published 2024-11-11, 09:00 a/m
© Reuters
PFE
-
NVAX
-
MRNA
-

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY).

The biotech firm’s shares jumped soared 13% in premarket trading following the announcement.

Novavax (NASDAQ:NVAX) disclosed last month that the trial had been paused after a participant who received the combination vaccine initially reported symptoms suggestive of motor neuropathy, which affects the nerves controlling muscle movement.

The company later submitted additional data to the FDA, clarifying that the participant’s symptoms were more accurately linked to amyotrophic lateral sclerosis (ALS), a neurological condition impacting nerve cells in the brain and spinal cord.

Novavax stated that assessments found no connection between the symptoms and its vaccine.

"We thank the FDA for their partnership and thorough review of the additional information provided as part of our response package," said Robert Walker, Chief Medical (TASE:PMCN) Officer of Novavax.

"The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine. We plan to start our Phase 3 trial as soon as possible."

A clinical hold is an FDA directive that instructs a drug manufacturer to delay or halt a planned clinical study. The move triggered a sharp drop in Novavax shares last month.

Novavax then stated that it did not believe there was a confirmed link between its vaccine and the reported nerve damage in the patient.

Public health officials consider Novavax's protein-based COVID vaccine to be a valuable choice for individuals hesitant to receive the mRNA vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

Unlike mRNA technology, which prompts cells to produce proteins that stimulate an immune response to COVID, Novavax’s approach relies on protein-based technology—a well-established method used for years in vaccines against diseases like hepatitis B and shingles.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.